CD44-specific A6 nano-short peptide enhances the targeting and mechanism of doxorubicin on the surface of polymers for multiple myeloma

In this study, we sought to prepare epirubicin immunonanoparticles and observe their antibody activity, drug release in vitro, and antitumor effects in vitro. Epirubicin nanoparticles (e-adm-nps) were synthesized using the polyelectrolyte complex method, and monoclonal antibody nanoparticles were synthesized using a chemical cross-linking method. The antibody activity of epirubicin monoclonal antibody nanoparticles (emadm ab nps) was detected by ELISA, the drug release in vitro was measured by ultraviolet spectrophotometry, and the cytotoxic effect in vitro was detected using a thiazole blue assay. The average particle size of e-adm-ab-nps was 0 190 (+/- 21) mm, and the antibody activity was well preserved. In vitro drug release analysis showed that e-admab-nps had sustained-release characteristics, and the cumulative release of e-adm-ab-nps reached 93.46% in 10 days. The cytotoxic effect of e-adm in vitro was time-dependent over 1 to 6 days, and dose-dependent over 1 to 10 days, although the difference between e-adm-ab-nps and e-adm at the same concentrations was not statistically significant (P > 0.05). E-adm-abnps show a sustained-release effect and immune activity, can prolong the effective time of e-adm for mouse multiple myeloma cells, and have no effect on the biological activity of epirubicin.